These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34636747)

  • 1. New therapeutic opportunities for women with low-grade serous ovarian cancer.
    Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
    Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
    Grisham RN; Iyer G
    Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutics in low-grade serous ovarian cancer.
    Cobb L; Gershenson D
    Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
    De Decker K; Wenzel HHB; Bart J; van der Aa MA; Kruitwagen RFPM; Nijman HW; Kruse AJ
    Acta Obstet Gynecol Scand; 2023 Mar; 102(3):246-256. PubMed ID: 36734363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular changes driving low-grade serous ovarian cancer and implications for treatment.
    Kelliher L; Yoeli-Bik R; Schweizer L; Lengyel E
    Int J Gynecol Cancer; 2024 Oct; 34(10):1630-1638. PubMed ID: 38950921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The highs and lows of serous ovarian cancer.
    Grisham RN; Manning-Geist BL; Chui MH
    Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BRAF pathway in low-grade serous ovarian cancer.
    Perrone C; Angioli R; Luvero D; Giannini A; Di Donato V; Cuccu I; Muzii L; Raspagliesi F; Bogani G
    J Gynecol Oncol; 2024 Jul; 35(4):e104. PubMed ID: 38768941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
    Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
    Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics of low-grade serous carcinoma in effusions.
    Doutel D; Davidson B; Nitschke Pettersen IK; Torgunrud A
    Cytopathology; 2023 Mar; 34(2):99-105. PubMed ID: 36609991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
    McLachlan J; Gore M; Banerjee S
    Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.